Kazia Therapeutics Ltd (KZIA) FinancialsKZIAKazia Therapeutics Ltd

Kazia Therapeutics Ltd (KZIA) generates its revenue primarily from Consumer Business, which accounts for 100.0% of total sales, equivalent to $10.31K. Understanding this concentration is critical for investors evaluating how KZIA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Kazia Therapeutics Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8320.33%, while the net margin is -7800.31%. These profitability ratios, combined with a Return on Equity (ROE) of -102.73%, provide a clear picture of how effectively KZIA converts its operational activities into shareholder value.

In the context of the broader market, KZIA competes directly with industry leaders such as IMDX and PMVP. With a market capitalization of $98.07M, it holds a leading position in the sector. When comparing efficiency, KZIA's gross margin of 100.00% stands against IMDX's 65.69% and PMVP's N/A. Such benchmarking helps identify whether Kazia Therapeutics Ltd is trading at a premium or discount relative to its financial performance.

Kazia reported a gross margin of 100% for Q1 2026, but also a significant net loss of -9,951,035 AUD, indicating financial strain despite high gross margins.